Evolving Paradigms in AML Live
Welcome to the registration website for

Evolving Paradigms in AML

Join us for this live satellite symposium during the Society of Hematologic Oncology (SOHO) annual meeting and earn 1.0 credit hour of continuing education. The meeting includes breakfast.

Thursday, September 13, 2018
6:30 am – 8:00 am CT
Hilton Americas-Houston
Grand Ballroom G-L
1600 Lamar Street
Houston, Texas 77010

This is an independent satellite symposium during the SOHO 2018 meeting.



PROGRAM OVERVIEW

Don't miss this educational opportunity to meet and interact with four thought leaders in AML.

The medical landscape of AML continues to evolve, as evidenced by the recent approval of four new agents in 2017 and the anticipated approval of additional novel agents in the very near future. An explosion of clinical trials and updated practice guidelines – coupled with a multitude of therapies in late-stage development – has created the vast challenge of staying up-to-date with clinical evidence impacting practice and patient outcomes. Our experts will provide a high-level overview of the latest data from newly diagnosed to relapsed disease, focusing on the most current therapeutic landscape.

The panelists will provide an opportunity for lively interaction with the audience, allowing sufficient time to present individual questions and clinical challenges for discussion.

TARGET AUDIENCE

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
  • Summarize key considerations which drive the clinical decision-making process in newly diagnosed versus relapsed/refractory AML
  • Identify issues requiring special consideration in older AML patients and patients with high-risk disease
  • Outline practical strategies for effectively incorporating new and recently approved agents and combination regimens for AML into clinical practice, including treatment selection, dosing and adverse event management
  • Identify key clinical trial information which may further impact clinical practice in AML in the future
FACULTY
Farhad Ravandi, MD Farhad Ravandi, MD Chair
Professor, Department of Leukemia
Division of Cancer Medicine
Chief, Section of Developmental Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD Naval Daver, MD
Assistant Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD Guillermo Garcia-Manero, MD
Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Richard Stone, MD Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts

AGENDA

6:30 am Registration and Breakfast

7:00 am Program Begins
  • Welcome/Overview; The Expanding Treatment Paradigm in AML
  • FLT3 Mutations in AML: Navigating the New and Emerging Therapeutic Options
  • High-Risk AML: New Therapeutic Option and Trials in Progress
  • Recent Developments and Current Status of Immunotherapy in AML
  • The Impact of New and Emerging IDH Inhibitors on Clinical Practice
  • Future Directions in AML
  • Audience Q & A

Bring Your Own Device A download link to the presentation slides will be provided prior to the meeting. If you would like to follow along with the slides, please bring your laptop, tablet, or other mobile device to the program.


ACCREDITATION  
MediCom Worldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit.
Universal Activity Number: 827-0000-18-020-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

MediCom Worldwide, Inc. NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-020-079

DISCLOSURE
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

AMERICANS WITH DISABILITIES ACT/SPECIAL NEEDS
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation. If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please call 800-408-4242 no later than 14 days prior to the activity.

INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating in this activity. In order to receive credit, all participants must complete the Activity Evaluation Form following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. CME/CNE certificates will be emailed 4 weeks following receipt of a completed, qualified form. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 128 or email lisa@medicaled.com.

Provided by
MediCom Worldwide, Inc.
Supported by educational grants from Agios Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Helsinn, and Jazz Pharmaceuticals, Inc.